Related Experiment Video
Updated: Apr 25, 2026

How to Use the H1 Deep Transcranial Magnetic Stimulation Coil for Conditions Other than Depression
Published on: January 23, 2017
Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study
J P John1, A Lukose1, S Manjunath1
1Multimodal Brain Image Analysis Laboratory (MBIAL) NIMHANS, Bangalore, India.
Introduction:
Memantine, an uncompetitive N-methyl D-aspartate receptor (NMDAR) open-channel blocker holds great promise for its potential clinical effectiveness as add-on therapy to on-going treatment with antipsychotics.
Methods:
We report here the results of a chart review-based retrospective case series study that examined the effectiveness of off-label use of memantine in patients with schizophrenia when used as adjunctive therapy to standard neuroleptic therapy.
Results:
17 of the 26 patients, whose case files were reviewed using a study-specific proforma showed clinical improvement in positive and/or negative psychopathology as well as in cognitive and/or functional domains. The doses of on-going antipsychotic medications could be reduced in a sizeable number of responders. None of the subjects reported serious adverse events.
Discussion:
Memantine holds great promise as adjunctive therapy for treatment of schizophrenia. Randomized controlled trials, wherein memantine is administered at adequate doses for an adequate period of time to ongoing antipsychotic treatment are required to confirm its efficacy in alleviating symptoms of schizophrenia.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Treatment
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Antidepressant Drugs: MAOIs and Other Agents
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Antiepileptic Drugs: Glutamate Antagonists

